Authors' recommendations: CONCLUSIONS High quality evidence indicates that in neutropenic patients with HIV infection, treatment of oral candidiasis with posaconazole does not have any advantage over clinical healing when compared with fluconazole; but it does promote fungus healing. In neutropenic patients after chemotherapy due to acute myeloid leukemia or myelodysplastic syndrome, prophylaxis with posaconazole promoted decrease in invasive fungal infection, invasive aspergillosis and mortality when compared with fluconazole and itraconazole. In hematopoietic cell host patients with significant graft-versus-host-disease, prophylaxis with posaconazole did not prove to be superior to fluconazole in decreasing invasive fungal infection, while fluconazole decreased invasive aspergillosis. The clinical practice guidelines consulted recommend posaconazole in mucocutaneous candidiasis in case of fluconazole-resistance or intolerance in HIV patients. In neutropenic patients due to blood cancers and/or hematopoietic cell receptors with graft-versus-host-disease, posaconazole is recommended as prophylaxis against candidiasis and invasive aspergillosis. The coverage policies consulted suggest covering posaconazole for the indications recommended by the clinical practice guidelines. It is also covered by the Unique Reimbursement System in Argentina.

Project Status: Completed

Year Published: 2017

URL for published report: https://www.iecs.org.ar/home-ets/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Argentina

Organisation Name: Institute for Clinical Effectiveness and Health Policy

Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA

Contact Name: info@iecs.org.ar

Contact Email: info@iecs.org.ar

Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)